CD4 and progressive multifocal leukoencephalopathy: However, in comparison to the infliximab-treated patients, the CD4+ T cell count at last follow-up (median time from PML diagnosis until last the follow-up and CD4+ T cell determination 70 months, range 40–92 months) was lower in these two patients in comparison to the infliximab-treated patients (see Table 1).